Novartis has suffered a defeat in its legal defence of chronic heart failure therapy Entresto, which accounted for around 11% of its revenues last year, but has vowed to take the case to appeal.

Entresto is a brand-name prescription medication containing sacubitril and valsartan. The FDA approved generic versions of Entresto in May 2024, and the drug was launched in July 2025. According to ...

By Bhanvi Satija and Marleen Kaesebier LONDON, April 28 (Reuters) - Novartis posted first-quarter core operating profit and ...

Novartis has started to show the effects of its patent cliff more strongly, with sales and profits falling in the first ...

Case Name: In re Entresto, 125 F.4th 1090 (Fed. Cir. Jan. 10, 2025) (Circuit Judges Lourie, Prost, and Reyna presiding; Opinion by Lourie, C.J.) (Appeal from D. Del ...

Entresto, a combination of an old drug valsartan with a novel neprilysin inhibitor sacubitril from Novartis, which was approved in July for treating heart failure, has been ear-marked by analysts as a ...

Entresto (sacubitril/valsartan) is a brand-name drug prescribed to treat heart failure. Entresto has interactions with some other drugs and certain supplements ...

Entresto (sacubitril/valsartan) has interactions with alcohol, other medications, and some supplements. For example, Entresto can interact with potassium supplements ...

Some people with heart failure need to take multiple medicines each day in order to keep their symptoms under control. Heart failure not only leads to issues in the heart but other organs in the body ...